Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
A phase 3 trial testing GFH375 in pancreatic ductal adenocarcinoma, now recruiting.
Overview
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT07262567, led by Genfleet Therapeutics (Shanghai), and recruiting when checked on 2026-09-11. Official title: A Multicenter, Open-Label, Randomised Controlled Phase III Study to Compare the Efficacy and Safety/Tolerability of GFH375 Monotherapy Versus Investigator's Choice of Chemotherapy in Patients With Previously Treated KRAS G12D-Mutant Metastatic Pancreatic Cancer. Planned enrolment is 320 participants (estimated). The study started in 2025-12-04 and primary completion is expected in 2027-06. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Shares GFH375, GenFleet Therapeutics and the tag ctgov-ingest.
- TrialA Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialStudy of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.
- TrialA Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag ctgov-ingest.